Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide

European Journal of Haematology

Volumn 90, Issue 2, 2013, Pages 162-163

  Beckers, Mariëlle M ^a   Huls, Gerwin ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angioimmunoblastic lymphoma; Lenalidomide; Therapy refractory

Indexed keywords

CETIRIZINE; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; PREDNISONE; RANITIDINE; VALACICLOVIR; VINCRISTINE;

ADULT; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSPNEA; EDEMA; EOSINOPHILIA; EPSTEIN BARR VIRUS INFECTION; FOLLOW UP; HUMAN; INTERSTITIAL PNEUMONIA; LYMPHADENOPATHY; MALE; MOON FACE; MUSCLE WEAKNESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRURITUS; RASH; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PREDNISONE; REMISSION INDUCTION; THALIDOMIDE;

EID: 84872787840     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12053     Document Type: Article

References (8)

1. Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 2012 Aug 6. [Epub ahead of print].
2. Dunleavy K, Wilson WH, Jaffe ES. Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Curr Opin Hematol 2007;14:348-53.
3. Lonial S, Cavenagh J. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. Br J Haematol 2009;145:681-708.
4. Kelaidi C, Eclache V, Fenaux P. The role of lenalidomide in the management of myelodysplasia with del 5q. Br J Haematol 2008;140:267-78.
5. Leitch HA, Buckstein R, Shamy A, Storring JM. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline. Crit Rev Oncol Hematol 2012 Aug 14. [Epub ahead of print].
6. Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, van der Jagt R, Johnston J, Belch A, Reiman T. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010;116:4541-8.
7. Rentschler J, Herrmann R, Fischer N, Potthast S, Vetter M. Lenalidomide in heavily pretreated angioimmunoblastic T-cell lymphoma (AITL). J Clin Oncol 2011;29: abstr e18552.
8. Fabbri A, Cencini E, Pietrini A, Gozetti A, Defina M, Fontanelli G, Mazzel MA, Voltrerrani L, Bocchia M. Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up. Hematol Oncol 2012 Nov 14. doi: 10.1002/hon.2038. [Epub ahead of print].